Healthcare provider profile · identity verified

Joel I Posner, MD

Internal Medicine · BRONX, NY · NPI 1356434575

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	845	262
Amlodipine Besylate	Amlodipine Besylate	675	212
Albuterol Sulfate Hfa	Albuterol Sulfate	346	90
Metformin Hcl	Metformin Hcl	323	100
Losartan Potassium	Losartan Potassium	283	85
Metoprolol Succinate	Metoprolol Succinate	275	87
Hydrochlorothiazide	Hydrochlorothiazide	230	63
Lisinopril	Lisinopril	189	60
Pravastatin Sodium	Pravastatin Sodium	179	54
Omeprazole	Omeprazole	177	68
Levothyroxine Sodium	Levothyroxine Sodium	167	59
Valsartan	Valsartan	163	60
Ozempic	Semaglutide	140	28
Simvastatin	Simvastatin	139	45
Nifedipine Er	Nifedipine	135	44
Fluticasone Propionate	Fluticasone Propionate	132	39
Eliquis	Apixaban	131	38
Rosuvastatin Calcium	Rosuvastatin Calcium	127	43
Gabapentin	Gabapentin	124	44
Tamsulosin Hcl	Tamsulosin Hcl	124	38
Metformin Hcl Er	Metformin Hcl	123	40
Jardiance	Empagliflozin	117	35
Carvedilol	Carvedilol	116	34
Janumet	Sitagliptin Phos/Metformin Hcl	115	31
Chlorthalidone	Chlorthalidone	101	35
Famotidine	Famotidine	101	31
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	97	26
Pantoprazole Sodium	Pantoprazole Sodium	86	29
Montelukast Sodium	Montelukast Sodium	77	27
Furosemide	Furosemide	76	25
Clopidogrel	Clopidogrel Bisulfate	72	19
Trulicity	Dulaglutide	66	14
Januvia	Sitagliptin Phosphate	65	21
Metoprolol Tartrate	Metoprolol Tartrate	65	19
Glipizide Er	Glipizide	63	16
Pregabalin	Pregabalin	62	14
Diclofenac Sodium	Diclofenac Sodium	60	30
Allopurinol	Allopurinol	56	18
Finasteride	Finasteride	55	16
Sertraline Hcl	Sertraline Hcl	55	16
Alcohol Prep Pads	Alcohol Antiseptic Pads	53	18
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	53	18
Isosorbide Mononitrate Er	Isosorbide Mononitrate	48	12
Meclizine Hcl	Meclizine Hcl	46	23
Single Use Swab	Alcohol Antiseptic Pads	46	25
Spironolactone	Spironolactone	44	13
Irbesartan	Irbesartan	42	12
Pioglitazone Hcl	Pioglitazone Hcl	42	16
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	41	13
Potassium Chloride	Potassium Chloride	41	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	40	15
Telmisartan	Telmisartan	40	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	39	14
Azelastine Hcl	Azelastine Hcl	38	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	37	13
Glimepiride	Glimepiride	35	13
Levetiracetam	Levetiracetam	35	suppressed
Trazodone Hcl	Trazodone Hcl	33	suppressed
Ezetimibe	Ezetimibe	32	suppressed
Hydralazine Hcl	Hydralazine Hcl	32	suppressed
Tresiba Flextouch U-100	Insulin Degludec	32	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	31	13
Synthroid	Levothyroxine Sodium	30	suppressed
Felodipine Er	Felodipine	29	11
Mounjaro	Tirzepatide	29	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	29	suppressed
Duloxetine Hcl	Duloxetine Hcl	28	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	28	suppressed
Farxiga	Dapagliflozin Propanediol	28	12
Colchicine	Colchicine	27	suppressed
Mirtazapine	Mirtazapine	27	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	25	suppressed
Lidocaine-Prilocaine	Lidocaine/Prilocaine	25	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	24	suppressed
Entresto	Sacubitril/Valsartan	24	suppressed
Fenofibrate	Fenofibrate	24	suppressed
Donepezil Hcl	Donepezil Hcl	23	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	23	15
Alendronate Sodium	Alendronate Sodium	22	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	22	suppressed
Warfarin Sodium	Warfarin Sodium	22	suppressed
Arnuity Ellipta	Fluticasone Furoate	21	suppressed
Ipratropium Bromide	Ipratropium Bromide	20	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	20	19
Symbicort	Budesonide/Formoterol Fumarate	20	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	20	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	19	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	19	suppressed
Myrbetriq	Mirabegron	19	suppressed
Atenolol	Atenolol	18	suppressed
Tresiba Flextouch U-200	Insulin Degludec	18	suppressed
Levemir Flexpen	Insulin Detemir	17	suppressed
Clonidine	Clonidine	16	suppressed
Fluocinonide	Fluocinonide	16	suppressed
Jentadueto	Linagliptin/Metformin Hcl	16	suppressed
Naproxen	Naproxen	16	suppressed
Rybelsus	Semaglutide	16	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	15	suppressed
Labetalol Hcl	Labetalol Hcl	15	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	15	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	15	suppressed
Benazepril Hcl	Benazepril Hcl	14	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	14	suppressed
Pyridostigmine Bromide	Pyridostigmine Bromide	14	suppressed
Repatha Syringe	Evolocumab	14	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	13	suppressed
Estradiol	Estradiol	13	suppressed
Ibuprofen	Ibuprofen	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Ventolin Hfa	Albuterol Sulfate	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Meloxicam	Meloxicam	12	suppressed
Memantine Hcl Er	Memantine Hcl	12	suppressed
Celecoxib	Celecoxib	11	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	11	suppressed
Linzess	Linaclotide	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Nebivolol Hcl	Nebivolol Hcl	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error